Bisphosphonates are synthetic analogues of pyrophosphate that inhibit bone resorption by their action on osteoclasts. In recent years, bisphosphonates have been used in children for treatment of a growing number of disorders associated primarily with generalized or localized osteoporosis, genetic and acquired metabolic bone diseases, heterotopic calcifications in soft tissues, and for hypercalcemia. In this review, the authors address the role of and experience with bisphosphonate therapy in disorders of childhood.
SrivastavaTAlonUS. The role of bisphosphonates in diseases of childhood. Eur J Pediatr. 2003;162:735-751.
2.
SchiblerDRussellRGFleischH. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. Clin Sci. 1968;35:363-372.
3.
BassettCADonathAMacagnoFPreisigRFleischHFrancisMD. Diphosphonates in the treatment of myositis ossificans. Lancet. 1969;2:845.
4.
ChavassieuxPMArlotMERedaCWeiLYatesAJMeunierPJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997;100:1475-1480.
5.
MoraSBachrachLGilsanzV. Noninvasive techniques for bone mass measurement. In: GlorieuxFHPettiforJMJuppnerH, eds. Pediatric Bone Biology and Diseases. New York, NY: Academic Press; 2003:304-319.
6.
GafniRIBaronJ. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA). J Pediatr. 2004;144:253-257.
7.
Eyre DR Biochemical markers of bone turnover. In: FavusMJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 3rd ed.Philadelphia, PA: Lippincott-Raven; 1996:114-119.
8.
GarneroPShihWJGineytsEKarpfDBDelmasPD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to aledronate treatment. J Clin Endocrinol Metab. 1994;79:1693-1700.
9.
MoraSPrinsterCProverbioMC. Urinary markers of bone turnover in healthy children and adolescents: age-related changes and effect of puberty. Calcif Tissue Int. 1998;63:369-374.
10.
Van BeekEHoekstraMvan de RuitMLowikCPapapoulosS. Structural requirements for bisphosphonates actions in vitro. J Bone Miner Res. 1994;9:1875-1882.
11.
RussellRGWattsNBEbetinoFHRogersMJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733-759.
12.
RogersMJGordonSBenfordHL. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12 suppl):2961-2978.
13.
CaranoATeitelbaumSLKonsekJDSchlesingerPHBlairHC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 1990;85:456-461.
14.
RoweDJHausmannE. The effects of calcitonin and colchicine on the cellular response to diphosphonate. Br J Exp Pathol. 1980;61:303-309.
15.
NishikawaMYamamotoMMurakamiTAkatsuTKugaiNNagataN. A third-generation bisphosphonate, YM175, inhibits osteoclast formation in murine cocultures by inhibiting proliferation of precursor cells via supporting cell-dependent mechanisms. J Bone Miner Res. 1998;13:986-995.
16.
HughesDEWrightKRUyHL. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478-1487.
17.
EzraAGolombG. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev. 2000;42:175-195.
18.
RussellRGCroucherPIRogersMJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 1999;9(suppl 2):S66-S80.
19.
ToussaintNDElderGJKerrPG. Bisphosphonates in chronic kidney disease: balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol. 2009;4:221-233.
20.
KauffmanRPOvertonTHShiflettMJenningsJC. Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature. Obstet Gynecol Surv. 2001;56:492-504.
21.
MelchiorRZabelBSprangerJSchumacherR. Effective parenteral clodronate treatment of a child with severe juvenile idiopathic osteoporosis. Eur J Pediatr. 2005;164:22-27.
22.
HoekmanKPapapoulosSEPetersACBijvoetOL. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab. 1985;61:952-956.
DevogelaerJPMalghemJMaldagueBNagant de DeuxchaisnesC. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16:360-363.
25.
HasegawaKInoueMSeinoYMorishimaTTanakaH. Growth of infants with osteogenesis imperfecta treated with bisphosphonate. Pediatr Int. 2009;51:54-58.
26.
RauchFTraversRParfittAMGlorieuxFH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000;26:581-589.
27.
AntoniazziFMontiEVenturiG. GH in combination with bisphosphonates treatment in osteogenesis imperfect. Eur J Endocrionol. 2010;163:479-487.
28.
AminSLaValleyMPSimmsRWFelsonDT. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum. 1999;42:1740-1751.
29.
PanigrahiIDasRRShardaSMarwahaRKKhandelwalN. Response to zolendronic acid I children with type III osteogenesis imperfect. J Bone Miner Metab. 2010;28:451-455.
30.
BishopNHarrisonRAhmedF. A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfect. J Bone Miner Res. 2010;25:32-40.
31.
LandCRauchFTraversRGlorieuxFH. Osteogenesis imperfect type VI in childhood and adolescence: effect of cyclical intravenous pamidronate treatment. Bone. 2007;40:638-644.
32.
AndiranNAlikasifogluAGoncNKandemirNYordamN. Cyclic pamidronate therapy in children with osteogenesis imperfect: results of treatment and follow-up after discontinuation. J Pediatr Endocrinol Metab. 2008;21:63-72.
33.
Kamoun-GoldratAGinisityDLe MerrerM. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci. 2008;116:195-198.
34.
MatarazzoPLalaRMasiGAndreoMAltareFde SanctisC. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15(suppl 3): 929-937.
35.
LandesbergREisigSFennoyISirisE. Alternative indications for bisphosphonate therapy. J Oral Maxillofac Surg. 2009; 67(5 suppl):27-34.
36.
PlotkinHRauchFZeitlinLMunnsCTraversRGlorieuxFH. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab. 2003;88:4569-4575.
37.
KellyMHBrillanteBCollinsMT. Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions. Osteoporos Int. 2008;19:57-63.
38.
TauCMautalenCCascoCAlyarezVRubinsteinM. Chronic idiopathic hyperphosphatesia: normalization of bone turnover with cyclic intravenous pamidronate therapy. Bone. 2004;35:210-216.
39.
CundyTWheadonLKingA. treatment of idiopathic hyperphosphatesia with intensive bisphosphonate therapy. J Bone Miner Res. 2004;19:703-711.
40.
SamuelRKatzKPapapoulosSEYosipovitchZZaizovRLibermanUA. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher’s disease. Pediatrics. 1994;94:385-389.
41.
DrakeWMHiornsMPKendlerDL. Hadju-Cheney syndrome: response to therapy with bisphosphonates in two patients. J Bone Miner Res. 2003;18:131-133.
42.
KuriyamDKMcElligottSCGlaserDWThompsonKS. Treatment of Gorham-Stout disease with zoledronic acid and interferon-α: a case report and literature reviewJ Pediatrc Hematol Oncol. 2010;32:579-584.
43.
ZacharinMCundyT. Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. J Pediatr. 2000;137:410-415.
44.
JulianBALaskowDADubovskyJDubovskyEVCurtisJJQuarlesLD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325:544-550.
45.
HomikJECranneyASheaB. A meta-analysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol. 1999;26:1148-1157.
46.
ReyesMLHernándezMIKingACorticosteroid-induced osteoporosis in children: outcome after two-year follow-up, risk factors, densitometric predictive cut-off values for vertebral fractures. Clin Exp Rheumatol. 2007;25:329-335.
47.
KikuchiYImakiireTYamadaM. Effect of risedronate on high-dose corticosteroid–induced bone loss in patients with glomerular disease. Nephrol Dial Transplant. 2007;22:1593-1600.
48.
BachrachSJKecskemethyHHHarckeHTHossainJ. Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. Dev Med Child Neurol. 2010;52:837-842.
49.
HoweWDavisEValentineJ. Pamidronate improves pain, well-being, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions. Dev Neurorehabil. 2010;13:31-36.
50.
ApkonSCollJ. Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy. Am J Phys Med Rehabil. 2008;87:139-143.
51.
ShawNJWhiteCPFraserWDRosenbloomL. Osteopenia in cerebral palsy. Arch Dis Child.1994;71: 235-238.
52.
BubbearJSGallAMiddletonFRFerguson-PellMSwaminathanRKeenRW. Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporos Int. 2011;22:271-279.
53.
SbrocchiAMForgetSLaforteDAzouzEMRoddC. Zoledronic acid for treatment of osteopenia in pediatric Crohn’s disease. Pediatr Int. 2010;52:754-761.
54.
ConwaySP. Impact of lung inflammation on bone metabolism in adolescents with cystic fibrosis. Paediatr Respir Rev. 2001;2:324-331.
55.
HaworthCSSelbyPLWebbAKMawerEBAdamsJEFreemontTJ. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis. Lancet. 1998;352:1753-1754.
56.
HaworthCSSelbyPLAdamsJEMawerEBHorrocksAWWebbAK. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax. 2001;56:314-316.
57.
SrivastavaTHaneyCJAlonUS. Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res. 2009;24:334-337.
58.
SrivastavaTDaiHHaneyCJAlonUS. Serum 25-hydroxyvitamin D level and acute-phase reaction following initial intravenous bisphosphonate. J Bone Miner Res. 2011;26:437-438.
59.
VichinskyEP. The morbidity of bone disease in thalassemia. Ann N Y Acad Sci. 1998;850:344-348.
60.
MorabitoNLascoAGaudioA. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int. 2002;13:644-649.
61.
GilfillanCPStraussBJRoddaCP. A randomized double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int. 2006;79:138-144.
62.
StraussAJSuJTDaltonVMGelberRDSallanSESilvermanLB. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001;19: 3066-3072.
63.
LethabyCWiernikowskiJSalaANaronhaMWebberCBarrRD. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. J Pediatr Hematol Oncol. 2007;29:613-616.
64.
BishopNJWilliamsDMCompstonJCStirlingDMPrenticeA. Osteoporosis in severe congenital neutropenia treated with granulocyte colony-stimulating factor. Br J Haematol. 1995;89:927-928.
65.
MorimotoAShiodaYImamuraT. Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis. Pediatr Blood Cancer. 2011;56:110-115.
66.
BalkeMCampanacciLGebertC. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer. 2010;10:462.
67.
CarpenterPAHoffmeisterPChesnutCH3rd. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host-disease. Biol Blood Marrow Transplant. 2007;13:683-690.
68.
WinstonMJSrivastavaTJarkaDAlonUS. Bisphosphonates for pain management in children with benign cartilage tumors. Clin J Pain. 2012;28:268-272.
69.
JamalSBauerDEnsrudKE. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22:503-508.
70.
WetmoreJBBenetLZKleinstuckDFrassettoL. Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology (Carlton). 2005;10:393-399.
71.
JokihaaraJPörstiIHKööbiP. Treatment of experimental renal osteodystrophy with pamidronate. Kidney Int. 2008;74:319-327.
72.
PalmerSCMcGregorDOStrippoliGF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 2007;(3):CD005015.
73.
GrendaRKarczmarewiczERubikJ. Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients—a prospective study. Pediatr Transplant. 2011;15:205-213.
74.
HaffnerDFischerDC. Can bisphosphonates play a role in the treatment of children with chronic kidney disease. Pediatr Nephrol. 2011;12:2111-2119.
75.
BuyseGSilbersteinJGoemansNCasaerP. Fibrodysplasia ossificans progressiva: still turning into wood after 300 years?Eur J Pediatr. 1995;154:694-699.
76.
RogersJGDorstJPGehoWB. Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva. J Pediatr. 1977;91:1011-1014.
77.
NucciAQueirozLDSantosADCamargoEEMoura-RibeiroMV. Fibrodysplasia ossificans progressiva: case report. Arg Neuropsiquiatr. 2000;58:342-347.
78.
RutschFBöyerPNitschkeY. Hypophosphatemia, hyperphosphaturia and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet. 2008;121:133-140.
AuronATalLSrivastavaTAlonUS. Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates. Pediatr Nephrol. 2009;24:613-617.
81.
ChatterjeeMSpeiserPW. Pamidronate treatment of hypercalcemia caused by vitamin D toxicity. J Pediatr Endocrinol Metab. 2007;20:1241-1248.
82.
EzguFSBuyanNGunduzMTumerLOkurIHasanogluA. Vitamin D intoxication and hypercalcemia in an infant treated with pamidronate infusions. Eur J Pediatr. 2004;163:163-165.
83.
BereketAErdoganT. Oral bisphosphonate therapy for vitamin D intoxication of the infant. Pediatrics. 2003;111:899-901.
84.
SangunODundarBNErdoganE. Severe hypercalcemia associated with Williams syndrome successfully treated with pamidronate infusion therapy. J Pediatr Endocrinol Metab. 2011;24:69-70.
85.
CagleAPWaguespackSGBuckinghamBAShankarRRDimelgioLA. Severe infantile hypercalcemia associated with Williams syndrome successfully treated with intravenously administered pamidronate. Pediatrics. 2004;114:1091-1095.
86.
OliverBMastagliaSRMautalenCGravanoJCPardo ArgerichL. Long-term control of hypercalcemia in an infant with Williams-Beuren syndrome after a single infusion of bisphosphonate (pamidronate). Acta Paediatr. 2004;93:1002-1003.
SaiaGBlandamuraSBettiniG. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg. 2010;68:797-804.
89.
SchwartzSJosephCIeraDVuDD. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series. J Can Dent Assoc. 2008; 74:537-542.
90.
IllidgeTMHusseyMGoddenCW. Malignant hypercalcemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol). 1996;8:257-258.
91.
LanzaFL. Bisphosphonates: oesophageal and gastric toxicity—fact or fiction. Ital J Gastroenterol Hepatol. 1998;30:143-145.
92.
TaggartHBologneseMALindsayR. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc. 2002;77:262-270.
93.
RobinsonRENahataMCHayesJRBatiskyDLBatesCMMahanJD. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy. 2004;24:195-197.
94.
RothenbuhlerAMarchandIBougneresPLinglartA. Risk of corrected QT interval prolongation after pamidronate infusion in children. J Clin Endocrinol Metab. 2010;95:3768-3770.
95.
MunnsCFRauchFZeitlinLFassierFGlorieuxFH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfect patients receiving pamidronate. J Bone Miner Res. 2004;19:1779-1786.
96.
WaterhouseKMAuronASrivastavaTHaneyCAlonUS. Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children. Pediatr Nephrol. 2007;22:282-287.
97.
Van Persijn van MeertenELKroonHMPapapoulosSE. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology. 1992;184:249-254.
